Mira Chaurushiya, Ph.D. is a Managing Director at Westlake BioPartners. She was previously a Partner at 5AM Ventures where she invested in and served on the boards of companies such as Enliven Therapeutics (ELVN), Escient Pharmaceuticals (acquired by Incyte), GlycoEra, Magnetic Insight, NodThera, Novome Biotechnologies, Precision Nanosystems (acquired by Danaher), Purigen Biosystems (acquired by BioNano), and TMRW.
Mira is a fellow of the Society of Kauffman Fellows. She previously served on the board of Biotech Connection Bay Area and currently serves on the board of Nucleate, both non-profit organizations that advance industry career and entrepreneurship opportunities for academic scientists. She was previously a Postdoctoral Fellow at Genentech. She received her Ph.D. in Biological Sciences at the University of California, San Diego, in conjunction with the Salk Institute, where she was awarded the Martin Kamen Thesis Prize in Biochemistry for her studies in viral infection and cancer. She received a B.A. in Biology with Distinction in the Senior Thesis from Carleton College.